CeNeReg: Positive results reported in a Phase 2b trial in the regeneration of spinal cord of paraplegics
19-12-2024 – The clinical trial evaluated the safety and efficacy of NG101, a recombinant human antibody that neutralizes the growth-inhibiting protein Nogo-A, on recovery in patients with acute cervical traumatic spinal cord injury.
The placebo-controlled study involved close to 130 patients and was executed in 13 different clinics across the Europe, including Switzerland, Germany, Czech Republic and Spain.
"It is the largest study to date that shows that the spinal cord of paraplegics can regenerate," says Armin Curt from the Balgrist University Hospital in Zurich, who co-initiated and organized the study.
The study showed clear improvements: 60 percent of participants who received the full treatment achieved the maximum level of self-care - twice as many as those on placebo.
"We are very pleased with the result because these improvements make a big difference for those affected," says Martin Schwab, Swiss neuroscientist at the University of Zurich who led the study.
Source: Tages Anzeiger - DE version / EN version
